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Abstract 
Background: Several inflammatory molecules participate in the immune response to malaria. Interleukin (IL)-18 is 
an inflammatory cytokine activated by NLRP3 inflammasomes. In clinical falciparum malaria, with and without HIV co-
infection, data on IL-18 and in particular on its binding protein, IL-18bp, is scarce.
Methods: Clinical data and blood samples were collected from adults in Mozambique with P. falciparum infection, 
with (n = 70) and without (n = 61) HIV co-infection, from HIV-infected patients with similar symptoms without malaria 
(n = 58) and from healthy controls (n = 52). In vitro studies were performed in endothelial cells using hemozoin 
crystals.
Results: (i) IL-18 and IL-18bp were markedly up-regulated during falciparum malaria with particular high levels in 
malaria patients co-infected with HIV and severe malaria disease. (ii) In the malaria group as a whole, both IL-18 and 
IL-18bp were positively correlated with disease severity, parasitemia, and endothelial cell activation as assessed by 
vWF in plasma. (iii) Whereas there was no change in IL-18 levels in malaria patients co-infected with HIV during follow-
up, the patients with malaria only had slightly increased IL-18 levels. Further, the IL-18pb levels declined and thereby 
contributed to an increase in IL-18/IL-18bp ratio in all subgroups of malaria patients. (iv) IL-27, previously shown to be 
up-regulated in this malaria cohort, markedly induced a release of IL-18bp from endothelial cells in vitro, and notably, 
this presumably anti-inflammatory effect was counteracted by hemozoin.
Conclusions: Our findings suggest that the IL-18 system could be an important mediator in the immune pathogen-
esis during falciparum malaria, potentially also representing a target for therapy.
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Introduction
Plasmodium falciparum (P. falciparum) malaria is an 
important cause of morbidity and mortality in sub-Saha-
ran Africa. The interaction between the parasite and the 
immune system has been extensively examined both in 
experimental and clinical studies. These data illustrate 
that the balance between a well-adjusted and an over-
whelming immune response is critical for the outcome 
of falciparum malaria, mediating beneficial and harmful 
responses, respectively, in the infected host [1, 2].
Interleukin (IL)-18 is an inflammatory cytokine, acti-
vated by NLRP3 inflammasomes, and released from the 
cell promoting inflammatory responses (e.g., induction 
of interferon (IFN) γ release) in T cells and natural killer 
(NK) cells. The biological effects of IL-18 are augmented 
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by the IL-18 binding protein (IL-18bp) which acts as a 
soluble decoy receptor and circulates at > tenfold higher 
level than IL-18. IL-18 binds to IL-18bp with an affin-
ity significantly higher than that of IL-18 receptor α [3, 
4]. Whereas IL-18 may have protective effects in various 
models of experimental malaria [5], high levels of IL-18 
have been associated with disease severity in clinical P. 
falciparum infection [6–8]. However, few studies, with a 
relative low number of patients, have examined circulat-
ing IL-18 levels in falciparum malaria [6–8]. Moreover, 
whereas we and others have shown that HIV infection 
is associated with increased IL-18 levels [9, 10], there 
are no data on how HIV infection influences IL-18 lev-
els in patients with P. falciparum infection. Furthermore, 
except for a large study in pregnant women [11], there are 
no data on IL-18bp in patients with falciparum malaria.
In the present study we examined plasma levels of 
IL-18 and IL-18bp in a cohort of non-pregnant adult 
patients with falciparum malaria with and without HIV 
co-infection, arriving at the Central Hospital of Maputo, 
Mozambique. IL-18 and IL-18bp levels were related to 
disease severity and parasitemia as assessed by quantita-
tive P. falciparum PCR analyses. We also examined the 
ability of the malarial pigment hemozoin to modulate 
the release of IL-18 and IL-18bp from endothelial cells. 
This was performed in the presence of IL-27, previously 
shown to be up-regulated in this malaria cohort [12]. 
We have also recently shown that IL-27 can promote 
NLRP3 activation, which is an important source for IL-18 
[13]. In addition, others have shown synergistic effect of 
IL-27 with IL-18 in NK cells [14] and IL-27 dependent 
up-regulation of IL-18bp in human ovarian cancer cells 
and skin resident cells [15, 16], suggesting some interac-
tions between IL-27 and IL-18 during inflammation and 
immune responses.
Materials and methods
Description of study design and participants
The study design has previously been described [17]. 
Briefly, in this prospective, cross-sectional study, we 
included 212 patients admitted to the Medical Emer-
gency Department in the Central Hospital of Maputo, 
Mozambique during seven months in two malaria 
peak seasons, from 2011 to 2012. Inclusion criteria 
were age ≥ 18  years, non-pregnancy, axillary tempera-
ture ≥ 38  °C and/or clinical suspected or confirmed 
malaria infection, and consent from patient or next of 
kin. Of the 212 screened patients, 129 had P. falciparum 
malaria as assessed by qualitative PCR, one by quanti-
tative PCR and one that had no PCR done had positive 
RDT and thick slide, giving a total of 131 falciparum 
malaria patients. Of the malaria patients, the median 
age was 37 years (18–84 years), 47% were women, and 
53% were co-infected with HIV-1 as assessed by PCR 
and/or serological tests. Of the malaria patients, 92% 
received quinine intravenously as a first-line therapy, 
4% received artemether intramuscularly, and the rest 
were treated with oral artemisinin combinations [17].
Severe malaria was found in 65% (85/131) of the 
patients, which meant that the patients had at least 
one of the WHO severity criteria [17, 18]. The sever-
ity criteria were: repeated convulsions and/or impaired 
consciousness with Glasgow Coma Score < 11, severe 
hypoglycaemia with plasma glucose < 2.2  mmol/L, 
severe anemia with Hb < 5  g/dL, renal failure with 
creatinine > 265  µmol/L, liver failure with biliru-
bin > 50  µmol/L, signs of respiratory failure with pul-
monary oedema on x-rays and/or respiratory rate > 30/
minute, bleeding or signs of coagulopathy, hyperpara-
sitemia > 4%, hyperthermia with temperature > 40  °C 
or signs of circulatory collapse/shock with systolic 
BP < 70  mmHg. 7.6% of the malaria patients died 
(10/128 of which nine were co-infected with HIV; miss-
ing data on outcome in three patients). The character-
istics of the patient groups at admission are shown in 
Table  1. The qualitative P. falciparum PCR in whole 
blood and the quantitative P. falciparum PCR in plasma 
were performed as previously described [19, 20].
For comparison, we also included 58 HIV-1-infected 
patients where malaria was excluded but with simi-
lar symptoms as the patients with falciparum malaria 
(fever, chills, headache, mental confusion, dyspnea, 
vomiting and/or diarrhea, myalgia and/or general 
malaise) and with similar HIV-related parameters as 
those co-infected with malaria (Table 1). These patients 
were diagnosed with, among others, tuberculosis, bac-
terial pneumonia, viral hepatitis, pneumocystis jeroveci 
pneumonia, toxoplasmosis encephalitis, urinary tract 
infection, and sepsis. Fifty-two apparently healthy HIV 
negative and malaria negative volunteers with median 
age 29 years (18–56 years, 40% women), were enrolled 
from hospital employees, and provided no history of 
chronic disease, had a subjective feeling of wellbeing 
and a healthy appearance evaluated by the researchers.
Blood sampling protocol
Blood samples from patients and healthy controls were 
collected from a peripheral vein into EDTA-tubes on 
admission and after 48 h. The tubes were immediately 
placed on melting ice and centrifuged within 30  min 
at 2000g for 20  min to obtain platelet-poor plasma. 
Plasma was aliquoted and stored at − 20  °C for 24  h; 
then at − 80 °C.
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Endothelial cell culture
Primary Human Aortic Endothelial cells (HAoECs) 
were obtained from PromoCell GmbH, Heidelberg, 
Germany. The cells were cultured in Endothelial Cell 
Growth Medium MV2 (PromoCell), passaged by treat-
ment with Trypsin/EDTA (0.04%/0.03%) and grown in 
48-well plates (Thermo Scientific, Roskilde, Denmark) 
coated with 1% gelatin (Sigma, St Louis, MO). In the 
experiments the cells were cultured with and without 
recombinant human (rh)IL-27 (100  ng/mL; R&D Sys-
tems, Minneapolis, MN) in Opti-MEM reduced serum 
medium (Gibco, Grand Island, NY) supplemented with 
5% FBS for 1 h before stimulated with different concen-
trations of chemically synthesized hemozoin (Invivogen, 
San Diego, CA) for 22  h. For evaluation of possible cell 
toxicity different concentration of hemozoin was tested 
in HAoEC cultures using Cytotoxicity Detection Kit from 
Sigma Aldrich (St. Louis, MO).
Supernatant and plasma analyses
Protein levels of IL-18 and IL-18bp in plasma and cell 
supernatants were measured by enzyme immunoassays 
(EIAs) from R&D Systems. The intra- and interassay 
coefficient of variation were < 10% for all assays. Plasma 
levels of von Willebrand factor (vWF) have previously 
been analysed and reported in this population [12] and 
now used in correlation analyses.
Real‑time quantitative RT‑PCR
Total RNA was obtained from HAoEC by using RNe-
asy spin columns (QIAGEN, Hilden, Germany). Sam-
ples were subjected to DNase treatment (RNase-Free 
DNase Set; QIAGEN) and stored at -80  °C until further 
analysis. cDNA synthesis was performed using qScript 
cDNA Supermix (Quanta Bio, Beverly, MA 01,915). Gene 
expression was examined by real-time quantitative (q)
PCR. mRNA detection of IL-18 and IL-18bp and the ref-
erence gene β-actin was assessed with SybrGreen prim-
ers (Sigma Aldrich, St. Louis, MO 63103): IL-18, forward 
primers (FP): TCT TCA TTG ACC AAG GAA ATCGG, 
reverse primers (RP): TCC GGG GTG CAT TAT CTC TAC; 
IL-18bp, FP: TGG AAG TGC CAC TGA ATG GA, RP: CCA 
TTG CCC AGC CAG TAG AG; β-actin, FP: AGG CAC 
CAG GGC GTGAT, RP: TCG TCC CAG TTG GTG ACG 
AT. The relative mRNA level of each transcript was cal-
culated by the ΔΔCt-method and normalized to controls.
Statistical analyses
The distribution of IL-27 and vWF was skewed and non-
parametric statistics were used throughout. For compari-
son between the diagnostic groups, Kruskal Wallis was 
Table 1 Clinical characteristics of the patient population at admission
Values in mean (min–max) or percentage and proportion. The 52 healthy controls are not included aDefined as jaundice/bilirubine > 50 µmol/L, bDefined as bleeding 
disturbances/hemolysis, cDefined as GCS ≤ 11, convulsions or confusion, dOne patient died of non-malarial cause, he was excluded, eSevere HIV = WHO stage 3 or 4, 
fCD4 T-cell count were only obtained in 8 (HIV only) and 11 (HIV + malaria) patients, gART = antiretroviral therapy = HIV treatment. ‘‘Effective’’ is defined as ‘‘Previous 
known ART and undetectable HIV-RNA in the plasma’’, in relation to all HIV-patients with and without malaria
Characteristic Malaria HIV Malaria + HIV
N 61 58 70
Age, years 40 (18–79) 39 (22–84) 40 (20–65)
Sex, females (% (n)) 41 (25) 50 (29) 50 (35)
Haemoglobin (g/dL) 11.2 (3.2–17.0) 8.9 (2.9–15.2) 9.4 (2.5–15.7)
Leukocytes (×  109/L) 6.9 (1.3–15.5) 8.2 (0.3–25.4) 7.8 (0.9–21.8)
Platelets (×  109/L) 124 (11–452) 220 (13–682) 90 (8–330)
Se-Creatinine (µmol/L) 127 (57–357) 161 (41–873) 223 (62–1529)
Se-Glucose (mmol/L) 8.7 (3.6–40.5) 6.1 (3.3–10.6) 6.12 (1.5–27.0)
Liver failure (%)a 5 (3/61) 7 (4/57) 17 (12/70)
Coagulation disturbance (%)b 2 (1/61) 0 13 (9/70)
Cerebral affection (%)c 25 (15/61) 33 (19/58) 31 (22/70)
Systolic blood pressure 122 (70–240) 115 (90–160) 115 (80–170)
Respiratory rate 22 (12–68) 29 (12–56) 24 (16–42)
Case fatality rate (%) 1.7 (1/59) 27.8 (15/54) 13.0d (9/69)
Duration of symptoms in days (median) 4.2 (1–28) 7 (1–365) 8.6 (1–180)
Severe  HIVe (%) n.a 83 (48/58) 59 (41/70)
HIV viral load in copies/mL (median) n.a 1.3 ×  104 1.8 ×  104
Median CD4 lymphocyte count (cells/μL)f n.a 136 206
Effective ART g prior to admission (%) n.a 19 (10/53) 14 (9/64)
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used a priori followed by Dunn’s multiple comparison 
test between individual groups. Wilcoxon matched-pairs 
signed rank test was used to compare changes from base-
line to follow-up within each diagnostic group. Spear-
man correlation was used to assess associations between 
variables. In the ex vivo experiments Student’s t test was 
used. A two-sided p < 0.05 was considered significant.
Results
IL‑18, IL‑18bp and their ratio in P. falciparum infection 
with and without HIV infection
The patient population is described in Table  1, consist-
ing of three groups of patients: (i) HIV-infected patients 
with similar symptoms as malaria patients but with nega-
tive test for P. falciparum infection (n = 58), (ii) malaria 
patients without HIV infection (n = 61) and (iii) malaria 
patients co-infected with HIV (n = 70).
There was a marked increase in plasma levels of IL-18 
in all three patient groups compared to healthy controls 
(Fig.  1A). Interestingly, however, whereas there were 
no significant differences between those with malaria 
only comparing severe and mild disease, patients with 
malaria co-infected with HIV had significantly raised 
IL-18 levels compared not only to those with com-
bined infection and mild disease, but also to all other 
subgroups of patients including those with malaria only 
and severe disease (Fig. 1A).
IL-18 bioactivity is attenuated by IL-18bp by prevent-
ing the binding of IL-18 to its receptor [21]. Interest-
ingly, plasma levels of IL-18bp showed a similar pattern 
as IL-18 with a marked increase in all the three patient 
groups compared to healthy controls with the highest 
levels in the malaria patients co-infected with HIV and 
severe disease (Fig. 1B). In fact, these patients, but not 
co-infected patients with mild malaria disease, showed 
increased levels of IL-18bp also as compared with HIV-
infected patients without malaria (Fig. 1B). The IL-18/
IL-18bp ratio could potentially represent an estimate 
on IL-18 bioactivity. As depicted in Fig.  1C, this ratio 
showed no differences between the different malaria 
and severity groups, even as compared with healthy 
controls, potentially reflecting a rise in both IL-18 and 
IL-18bp in the patient groups.
Fig. 1 Plasma levels of IL-18 (A), IL-18bp (B) and the C IL-18/IL-18bp ratio according to severity. IL-18 and IL-18bp were measured in plasma in 
patients with HIV infection with febrile symptoms but without malaria (n = 58), patients with falciparum malaria without (M, n = 61 of which 28 with 
severe disease) and with HIV infection (HIV + M, n = 70 of which 47 with severe disease). For comparison, data from healthy controls (CTR, n = 52) 
are also included. Lines in the scatter plot represent the median and 25–75th percentiles. #p < 0.001 vs. all patient groups; *p < 0.05, ***p < 0.001 
versus HIV + M with severe malaria. In A the line with * indicates the Malaria without HIV group as a whole
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Associations of IL‑18 and IL‑18bp with clinical 
and biochemical characteristics in patients with P. 
falciparum infection with and without HIV infection
In malaria patients as a whole, IL-18 correlated positively 
with degree of parasitemia (assessed by qPCR), disease 
severity (defined by the WHO criteria [18]) and degree 
of endothelial cell activation (assessed by plasma vWF 
levels) and negatively with haemoglobin levels, platelet 
counts and kidney function (assessed by eGFR) (Table 2 
and Fig.  2). Regarding parasitemia and kidney func-
tion, a similar pattern was seen in both the two malaria 
groups. Association with disease severity and vWF, this 
was found in malaria patients co-infected with HIV and 
in malaria patients only, respectively. No correlations 
with haemoglobin levels or platelet counts was found in 
the two groups of malaria patients with or without HIV 
(Table  2). Moreover, in the malaria patients as a whole 
IL-18bp correlated positively with degree of parasitemia, 
disease severity, IL-18 levels and plasma vWF and nega-
tively with platelet counts and kidney function, but in 
contrast to IL-18, IL-18bp levels were not correlated 
with haemoglobin levels except from a positive associa-
tion in malaria patients co-infected with HIV (Table  2). 
Moreover, whereas IL-18 and IL-18bp were significantly 
Table 2 Correlation between IL-18 and IL-18bp and clinical data in patients
Not all data wereavailable in all patients. qMalPCR, quantitative PCR of falciparum malaria inplasma; severity, disease severity according to WHO classification, 
seeMethods; eGFR, estimated glomerular filtration rate; WBC, total white blood cell counts; vWF, von Willebrandfactor. *Correlation is significant at the 0.05 level 
(2-tailed). **Correlationis significant at the 0.01 level (2-tailed)
IL‑18 IL‑18bp
M M + HIV All M M + HIV All
IL-18bp 0.42** 0.09 0.32** – – –
qMalPCR 0.37** 0.25* 0.27** 0.41** 0.43** 0.42**
eGFR − 0.42** − 0.29* − 0.34** − 0.46** − 0.34** − 0.38**
Haemoglobin − 0.07 − 0.22 − 0.22* 0.18 0.26* 0.12
Platelets − 0.21 − 0.17 − 0.20* − 0.51** − 0.37** − 0.46**
Neutrophils − 0.13 − 0.30* − 0.26* 0.23 − 0.07 0.03
Lymphocytes 0.10 0.32 0.25* − 0.36* 0.01 − 0.12
WBC 0.29* 0.07 0.18 0.28* 0.03 0.14
vWF 0.46** 0.22 0.38** 0.38** 0.03 0.25**
Severity 0.07 0.30* 0.30** 0.15 0.11 0.18*
IL− 27 0.52** 0.13 0.30** 0.59** 0.44** 0.51**
Fig. 2 Scatterplots showing correlations (Spearman) between IL-18, IL-18bp and different parameters. Associations with parasitemia (qMalPCR), 
disease severity (the disease severity score was based on the WHO definition for malaria severity, see methods), plasma vWF, platelet counts 
and kidney function (eGFR) is shown. †log transformed for presentation. Numbers in graphs represent the correlation coefficient (rho) with red 
representing malaria, blue representing malaria + HIV and black all malaria patients. *p < 0.05, **p < 0.01
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correlated in patients with malaria without accompany-
ing HIV infection, this was not seen in malaria patients 
co-infected with HIV (Table 2). The most important cor-
relations for IL-18 and IL-18bp are also shown in Fig. 2.
Plasma levels of IL‑18 and IL‑18bp during follow‑up
In 77 patients (HIV without malaria [n = 49], malaria 
only [n = 6], malaria and HIV [n = 22]) we also had fol-
low-up samples taken in the hospital 48  h after admis-
sion (Fig. 3). Whereas there were no changes in plasma 
IL-18, IL-18bp and IL-18/IL-18bp ratio during follow-up 
in HIV-infected patients without malaria, the malaria 
patients showed a marked significant increase in IL-18/
IL-18bp ratio independent of co-infection with HIV and 
disease severity (Fig.  3). This pattern seemed primar-
ily to reflect a decrease in IL-18bp in all sub-groups of 
patients, whereas IL-18 did not change in patients with 
malaria and HIV but actually increased in patients with 
malaria only. Finally, during follow-up 10 patients with 
falciparum malaria of which 9 were co-infected with HIV 
died (in-hospital mortality), and these 10 non-survivors 
had significantly higher IL-18 levels than the 121 sur-
vivors (median [25th, 75th percentile] 7.5 [3.4, 10.1] vs. 
3.3 [2.0, 5.5] p = 0.016). In contrast to IL-18, high levels 
of IL-18bp or IL-18/IL-18bp were not associated with in-
hospital mortality.
Effects of hemozoin and rhIL‑27 on IL‑18 and IL‑18bp 
release from endothelial cells
We have recently shown that IL-27 may promote NLRP3 
activation, an important source of IL-18 [13]. IL-27 has 
recently also been shown to increase IL-18bp in skin 
resident cells and in human ovarian cancer cells [15, 16]. 
However, no data exist on the effect of IL-27 on IL-18bp 
in endothelial cells that are more relevant for malaria 
infection. We recently demonstrated increased plasma 
IL-27 in this study population, positively correlated with 
degree of parasitemia [12], and as shown in Table 2, IL-27 
was significantly correlated with IL-18bp in both malaria 
groups, and in malaria patients without HIV, IL-27 was 
also correlated with IL-18. We therefore next examined 
the ability of IL-27 to modulate the release of IL-18 and 
IL-18bp from endothelial cells with and without hemo-
zoin exposure. Whereas hemozoin stimulation alone did 
not induce any release of IL-18 or IL-18bp in endothe-
lial cells, hemozoin in combination with IL-27 induced 
a modest increase in IL-18 levels, being statistically sig-
nificant at the lowest hemozoin concentration (Fig. 4A). 
However, the effect of IL-27 was rather modest, in par-
ticular at the mRNA levels, with a potential additive and 
not synergistic effects of IL-27 on the IL-18 release when 
given together with the lowest hemozoin concentration. 
Moreover, IL-27 markedly promoted release of IL-18bp 
Fig. 3 Plasma levels of IL-18 (A), IL-18bp (B) and the C IL-18/IL-18bp ratio during follow-up. Plasma levels of IL-18 and IL-18bp at admission and 
follow-up (FU, 48 h after admission) were available in 22 patients with HIV infection without malaria and in patients with falciparum malaria without 
(n = 29, of which 14 with severe disease) and with HIV infection (HIV + M, n = 48 of which 33 with severe disease). Lines in the scatter plot represent 
the median and 25–75th percentiles. *p < 0.05, ***p < 0.001 versus levels at admission
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from endothelial cells and interestingly, the stimulating 
effect of IL-27 on IL-18bp release was markedly and dose 
dependently attenuated when co-incubated with hemo-
zoin (Fig. 4B). A similar pattern was seen at the mRNA 
level (Fig. 4C, D).
Discussion
Several inflammatory mediators participate in the host 
response to malaria [1, 2], and in the present study we 
show a marked regulation of IL-18 and its binding pro-
tein IL-18bp during falciparum malaria, with particular 
high levels in patients with severe malaria disease that 
were co-infected with HIV. Moreover, during follow-up 
all malaria patients showed an increase in IL-18/IL-18bp 
ratio, irrespective of disease severity and co-infection 
with HIV primarily reflecting a decline in IL-18bp, 
suggesting a net inflammatory temporal effect in the 
IL-18 system. Finally, previous studies have shown that 
IFN-γ induce an up-regulation of IL-18bp as a poten-
tial counteracting mechanism [3]. Herein we show that 
IL-27, another cytokine with relation to T cell activa-
tion [12], markedly induced a release of IL-18bp from 
endothelial cells in  vitro, and notably, this presumably 
anti-inflammatory effect was counteracted by hemozoin. 
Our findings suggest that the IL-18 system could be an 
important mediator in the immunopathogenesis during 
falciparum malaria, potentially also representing a target 
for therapy.
Based on studies in experimental malaria it has been 
suggested that IL-18 could have a protective effect in the 
infected host, at least partly related to its effect on NK 
cells [5, 22]. Moreover, a study in Papua New Guinea, 
suggests that IL-18 decrease the risk of clinical malaria in 
children through a modulatory effect on T cells [23]. Fur-
ther, clinical studies in children have shown higher IL-18 
levels in uncomplicated compared with severe falciparum 
malaria [24]. There are also some reports on adult falcipa-
rum malaria patients having raised IL-18 levels; Whereas 
some studies have restricted the inclusion to uncompli-
cated malaria showing elevated IL-18 levels compared to 
controls [8], some report no differences between uncom-
plicated and severe malaria, while others, on the contrary 
show the highest IL-18 levels in severe malaria [6, 7, 25]. 
However, the number of patients included in these stud-
ies was relatively low and none of the studies focused on 
co-infection with HIV. In the present study that included 
Fig. 4 Effects of IL-27 on IL-18 and IL-18bp gene expression and release from hemozoin-exposed endothelial cells. Human aortic endothelial cells 
were primed with recombinant (rh)IL-27 (100 ng/mL, 1 h) and incubated with 10, 50 and 100 μg/mL hemozoin (Hz) for 22 h. IL-18 (A) and IL-18bp 
(B) were measured in supernatants from the cells with EIA. Gene expression analyses for IL-18 (C) and IL-18bp (D) were analyzed by qPCR, related 
to reference gene β-actin/TaqMan reference probes and normalized to unstimulated cells (US). Results are representatives of minimum three 
experiments and data are presented as mean and SEM. ***p < 0.001 versus US (white bar), ††p < 0.01 and †††p < 0.001 versus Hz (blue bars) and 
###p < 0.001 versus IL-27 (hatched bars)
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131 patients with falciparum malaria, we found mark-
edly raised levels of IL-18 in these patients compared 
with healthy controls with the highest levels in those co-
infected with HIV and severe malaria disease. Indeed, 
malaria patients without HIV had similar IL-18 level as 
HIV-infected patients with similar febrile symptoms but 
without falciparum infection, illustrating the “inflam-
matory” contribution of HIV. Moreover, IL-18 levels at 
inclusion were significantly associated with disease sever-
ity and the degree of parasitemia, as assessed by qPCR. 
This pattern may contrast to some studies in children 
and it is possible that the effect of IL-18 in P. falciparum 
infection may differ between adults and children.
Like several other inflammatory cytokines, IL-18 has 
its own endogenous antagonist, IL-18bp that effectively 
forms a 1:1 high affinity complex with IL-18, exhibiting 
a very low dissociation rate [3]. High levels of IL-18bp 
have been reported in various inflammatory conditions 
like septicemia and various autoimmune disorders [3]. 
Previously, increased levels of IL-18bp, together with a 
wide range of other inflammatory markers, have been 
associated with falciparum malaria in pregnancy in a 
large cohort of HIV negative women from Malawi [11]. 
However, the present study is the first report of IL-18bp 
in clinical falciparum malaria in non-pregnant adults 
showing a significant association with disease sever-
ity and parasitemia. Moreover, whereas there were no 
changes (malaria patients co-infected with HIV) or a 
modest increase (malaria only) in IL-18 levels during 
follow-up, IL-18bp levels markedly decreased in both 
malaria groups, potentially reflecting a marked shift to 
inflammation within the IL-18 system during hospi-
talization. Indeed, during follow-up there was a rise in 
IL-18/IL-18bp ratio in all subgroups of malaria patients. 
The clinical importance of this pattern is at present not 
clear, and importantly, by binding the anti-inflammatory 
cytokine IL-37 [3, 26, 27], IL-18bp could potentially also 
have inflammatory effects.
IL-18bp does not correspond to the extracellular ligand 
binding domain of the IL-18 receptor and is not released 
from the cells by protease activity but is rather encoded 
by a separate gene [3]. The regulation of IL-18bp is not 
fully characterized, but IFNγ has been shown to increase 
IL-18bp levels, potentially as a counteracting mecha-
nism to balance the inflammatory interaction between 
macrophages and T cells [3, 27]. In the present study, 
we show that IL-27 also markedly enhanced IL-18bp in 
endothelial cells both at the protein and mRNA level. We 
have recently shown increased IL-27 levels in this cohort 
of malaria patients potentially mediating both inflamma-
tory and anti-inflammatory effects [12] and our data in 
the present study suggest that IL-27 could balance the 
activity of the IL-18 system by increasing the level of 
IL-18bp. Notably, at least in vitro, this anti-inflammatory 
effect was markedly attenuated by hemozoin, particular 
at high concentrations. If this effect is also seen in vivo, 
it could reflect an inflammatory effect of falciparum-
derived hemozoin in the interaction between the para-
site and endothelial cells, potentially mediating harmful 
effects on the host.
The present study has some limitations, since the 
follow-up samples during hospitalization were only 
obtained in a subgroup of patients. Moreover, correlation 
data do not necessarily mean any causal relationship, and 
the clinical consequences of altered IL-18bp is still not 
clear. Also, the lack of data CD4 + T cell counts on most 
of the HIV-infected patients may limit the interpretation 
of the data from these patients. Finally, comparative data 
from patients with other types of malaria would have 
strengthened our study.
Conclusion
Our data add the IL-18/IL-18bp axis to the inflamma-
tory pathways that are dysregulated during falciparum 
malaria. Based on the availability of IL-18bp as a treat-
ment option in clinical trials [28], our data may suggest 
that this therapeutic approach also could be investigated 
in falciparum malaria.
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